Non-peptide BDNF Mimetics for TrkB Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents based on neurotrophins face challenges such as poor stability, low oral bioavailability, restricted central nervous system penetration, and ethical concerns, along with difficulties in producing sufficient quantities, limiting their effectiveness in treating neurological and non-neurological disorders.
Innovation Solution
Development of small molecule, non-peptidyl compounds with binding and/or modulation specificity for the TrkB receptor molecule, which can activate the receptor and potentially combine with TrkA or TrkC receptors to avoid interactions with p75 NTR and sortilin, thereby mimicking key regions of neurotrophin proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neurotrophins are used as therapeutic agents, then neural survival and function are promoted, but stability and serum half life are poor
Solution Approach 1:
The patent creates synthetic peptide copies of the neurotrophin BDNF that replicate its biological function of promoting neural survival while achieving improved stability. The synthetic peptides are designed to mimic the key functional regions of BDNF, particularly the β-turn loop 2 region, to achieve the desired therapeutic effect with enhanced pharmacological properties.
Solution Approach 2:
The patent modifies the molecular parameters of the original neurotrophin by creating truncated and modified peptide versions. Specifically, the invention uses peptides of approximately 2000 MW (compared to full-length BDNF), which changes the stability and pharmacokinetic parameters while maintaining the ability to activate TrkB receptors and promote neural survival.
2Reliability
If neurotrophins are administered therapeutically, then neural function is enhanced, but oral bioavailability is low
Solution Approach 1:
The patent changes the molecular size and structural parameters of the neurotrophin to create smaller peptide fragments (approximately 2000 MW) that have improved oral bioavailability. This parameter change allows the therapeutic agent to be more readily absorbed through the gastrointestinal tract while retaining the ability to cross the blood-brain barrier and activate central nervous system targets.
3Reliability
If neurotrophins are used for treatment, then neural survival is promoted, but central nervous system penetration is restricted
Solution Approach 1:
The patent segments the full-length BDNF protein into smaller functional domains, specifically utilizing the β-turn loop 2 region and other critical functional segments. This segmentation creates peptides of approximately 2000 MW that are small enough to penetrate the blood-brain barrier effectively while retaining the essential neurotrophic activity needed to promote neural survival.
4Reliability
If synthetic BDNF peptides are created to achieve neurotrophic effects, then neural survival is promoted, but molecular size is too large for medicinal compounds
Solution Approach 1:
The patent extracts the essential functional regions from the full-length BDNF protein, specifically isolating the β-turn loop 2 and other critical domains that are responsible for TrkB receptor activation and neurotrophic effects. This extraction creates minimized peptides that retain full biological activity while reducing molecular weight to approximately 2000 MW, making them suitable as medicinal compounds.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively treat a wide range of disorders, including neurological and non-neurological conditions, by promoting neural survival and function, enhancing plasticity, and inducing cementogenesis and periodontal regeneration, while minimizing adverse effects.
Implementation Method 1
compound having binding and/or modulation specificity for the TrkB receptor molecule
Data Source
Figure 1
AI summary
Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.